Tumor necrosis factor supports cancer vaccine

One of the things that makes cancer "successful" is its ability to hide from the immune system, and this can make it difficult to create effective cancer vaccines. This is partly because tumors create a solid ball of cells that make it hard for the immune cells to get inside, and once inside the environment either destroys the immune cells or stops them from working effectively.

Researchers from the University of Western Australia found that low doses of TNFα (tumor necrosis factor α) targeted to a pancreatic tumor enhanced the ability of immune cells (T cells) to get inside the tumor and helped them to survive by stabilizing the blood vessels in the tumor and improving blood flow.

The team combined this approach with an anticancer vaccine, and found that it improved the response to the vaccine. This is still early days, but this could be a route to improving responses to a range of cancer vaccines.

- read the press release
- see the abstract

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.